ReviewTropical medicine and health2026
The pharmaceutical industry's multifaceted role in neglected tropical disease control: from market failure to global health innovation.
Review in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeglected tropical diseases (NTDs) represent a profound market failure wherein pharmaceutical innovation systematically underserves populations with the greatest need. Despite affecting over 1.7 billion people globally, NTDs receive less than 2% of pharmaceutical research and development (R&D) investment.
objectiveThis review synthesises evidence on the pharmaceutical industry's evolving role in NTD control, examining both traditional commercial models and innovative partnerships that have reshaped the global health landscape, with particular attention to implementation mechanisms and concrete operational pathways.
methodsWe conducted a comprehensive analysis of WHO reports, G-FINDER data, peer-reviewed literature, and industry commitments spanning 2000-2024, focusing on drug development pipelines, mass drug administration programmes, and financing mechanisms.
resultsProduct Development Partnerships (PDPs) have delivered 183 approved products since 1999, though the majority represent reformulations or repurposed compounds rather than novel chemical entities (NCEs). Mass drug administration programmes have distributed over 17 billion treatments from pharmaceutical donations valued at approximately $30 billion (at wholesale prices), preventing millions of disability-adjusted life years. However, persistent innovation gaps remain: only 4 NCEs (0.5% of all new therapeutics 2000-2011) specifically targeted NTDs. Diagnostic development continues to lag due to commercial barriers and fragmented regulatory pathways.
conclusionsThe pharmaceutical industry's contribution to NTD control has evolved from minimal engagement to strategic partnerships blending philanthropic drug donation, nonprofit-led R&D, and market-based incentives. While mechanisms including Priority Review Vouchers and Advance Market Commitments show potential, their effectiveness remains debated in the literature, particularly regarding access provisions and additionality. Future progress requires sustained push funding for PDPs, multi-year donor commitments, expansion of WHO prequalification for diagnostics, and strengthened South-South technology-transfer partnerships with concrete implementation frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.